An integrated drug-likeness study for bicyclic privileged structures: From physicochemical properties to in vitro ADME properties

Molecular Diversity

Volumn 15, Issue 4, 2011, Pages 857-876

  Han, Chunyan ^a   Zhang, Jinlan ^a   Zheng, Mingyue ^b   Xiao, Yao ^a   Li, Yan ^a   Liu, Gang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

ADME; Drug likeness; Pharmacokinetic properties; Physicochemical properties; Privileged structure

Indexed keywords

2(1H) QUINOXALINONE DERIVATIVE; BENZIMIDAZOLE; BENZODIAZEPINE DERIVATIVE; BENZOFURAN DERIVATIVE; BENZOPYRAN DERIVATIVE; BENZOTHIAZINONE; BENZOTHIAZOLE; BENZOTHIOPHENE; BENZOXAZINONE DERIVATIVE; BENZOXAZOLE DERIVATIVE; BIPHENYL; CHROMONE DERIVATIVE; INDOLE; NAPHTHALENE; PURINE; PYRIDINIUM DERIVATIVE; QUINOLINE; QUINOLONE DERIVATIVE; QUIZOLINONE; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL TISSUE; ARTICLE; BICYCLIC PRIVILEGED STRUCTURE; CELL STRAIN CACO 2; COMBINATORIAL CHEMISTRY; COMBINATORIAL LIBRARY; COMPUTER MODEL; CORRELATION ANALYSIS; DATA BASE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG LIKENESS; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOXICITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYDROGEN BOND; IN VITRO STUDY; LIVER MICROSOME; MOLECULAR WEIGHT; NONHUMAN; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; WATER CONTENT;

ABSORPTION; ANIMALS; BICYCLO COMPOUNDS; CACO-2 CELLS; COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTATIONAL BIOLOGY; DRUG DESIGN; DRUG STABILITY; HUMANS; HYDROGEN BONDING; MOLECULAR WEIGHT; PERMEABILITY; PHYSICOCHEMICAL PROCESSES; RATS;

EID: 84855228916     PISSN: 13811991     EISSN: 1573501X     Source Type: Journal    
DOI: 10.1007/s11030-011-9317-2     Document Type: Article

References (74)

1. Dickson M, Gagnon JP (2004) Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 3: 417-429. doi:10.1038/nrd1382 (Pubitemid 38618124)
2. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 3:711-715. doi:10.1038/nrd1470 (Pubitemid 39173511)
3. Muegge I (2003) Selection criteria for drug-like compounds. Med Res Rev 23:302-321. doi:10.1002/med.10041 (Pubitemid 36457537)
4. Walters WP, Murcko MA (2002) Prediction of 'drug-likeness'. Adv Drug Deliver Rev 54:255-271. doi:10.1016/S0169-409X(02)00003-0 (Pubitemid 34260953)
5. Ghose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge- based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1:55-68. doi:10.1021/cc9800071
6. Oprea TI, Allu TK, Fara DC et al (2007) Lead-like, drug-like or "pub-like": how different are they?. J Comput Aid Mol Des 21:113-119. doi:10.1007/s10822-007-9105-3 (Pubitemid 46416670)
7. Wenlock MC, Austin RP, Barton P et al (2003) A comparison of physiochemical property profiles of development and marketed oral drugs. J Med Chem 46:1250-1256. doi:10.1021/jm021053p (Pubitemid 36428230)
8. Gleeson MP (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 51:817-834. doi:10.1021/jm701122q (Pubitemid 351304691)
9. Martin YC (2005) A bioavailability score. J Med Chem 48:3164-3170. doi:10.1021/jm0492002 (Pubitemid 40628036)
10. Chohan KK, Paine SW, Waters NJ (2006) Quantitative structure activity relationships in drug metabolism. Curr Top Med Chem 6:1569-1578. doi:10.2174/156802606778108960 (Pubitemid 44304615)
11. Castillo-Garit JA, Marrero-Ponce Y, Torrens F, Garcia-Domenech R (2008) Estimation of ADME properties in drug discovery: predicting Caco-2 cell permeability using atom-based stochastic and non-stochastic linear indices. J Pharm Sci 97:1946-1976. doi:10.1002/jps.21122
12. Grass GM, Sinko PJ (2001) Effect of diverse datasets on the predictive capability ofADMEmodels in drug discovery. Drug Discov Today 6:54-61. doi:10.1016/S1359-6446(01)00150-7
13. Bemis GW, MurckoMA (1996) The properties of known drugs. 1. Molecular frameworks. J Med Chem 39:2887-2893. doi:10.1021/ jm9602928 (Pubitemid 26251026)
14. Horton DA, Bourne GT, Smythe ML (2003) The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem Rev 103:893-930. doi:10.1021/cr020033s
15. Patchett AA, Nargund RP (2000) Privileged structures-an update. Annu Rep Med Chem 35:289-298. doi:10.1016/S0065-7743(00)35027-8
16. Evans BE, Rittle KE, Bock MG et al (1988) Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 31:2235-2246. doi:10.1021/jm00120a002 (Pubitemid 19001640)
17. Duarte CD, Barreiro EJ, Fraga CA (2007) Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem 7:1108-1119. doi:10.2174/138955707782331722 (Pubitemid 350200217)
18. Vistoli G, Pedretti A, Testa B (2008) Assessing drug-likeness- what are we missing?. Drug Discov Today 13:285-294. doi:10. 1016/j.drudis.2007.11.007
19. Good AC, Hermsmeier MA (2007) Measuring CAMD technique performance. 2. How"druglike" are drugs? Implications of random test set selection exemplified using druglikeness classificationmodels. J Chem Inf Model 47:110-114. doi:10.1021/ci6003493 (Pubitemid 46225566)
20. Li L, Wang Z, Chen Y et al (2007) Design and synthesis of novel tricycles based on 4H-benzo[1,4]thiazin-3-one and 1,1-dioxo-1,4- dihydro-2H-1lambda6- benzo[1,4]thiazin-3-one. J Comb Chem 9:959-972. doi:10.1021/cc0700501
21. Zhao HY, Liu G (2007) Solution-phase parallel synthesis of diverse 1,5-benzodiazepin-2-ones. J Comb Chem 9:1164-1176. doi:10.1021/cc7001149
22. Zhao HY, Liu G (2007) Solution-phase parallel synthesis of 2,3-dihydro-1,5-benzothiazepin-4(5H)-ones. J Comb Chem 9: 756-772. doi:10.1021/cc070036o
23. Wang Z, Yuan Y, Chen Y et al (2007) Parallel solution-phase synthesis of 4H-benzo[1,4]thiazin-3-one and 1,1-dioxo-1,4-dihydro- 2H-1lambda6-benzo[1,4] thiazin-3-one derivatives from 1,5- difluoro-2,4-dinitrobenzene. J Comb Chem 9:652-660. doi:10.1021/cc0601276
24. Yuan Y, Liu G, Li L et al (2007) Synthesis of diverse benzo[1,4]oxazin-3-one-based compounds using 1,5-difluoro-2,4- dinitrobenzene. JCombChem 9:158-170. doi:10.1021/cc060094u
25. Yang TM, Liu G (2007) Solution-phase parallel synthesis of 3,5,6- substituted indolin-2-ones. J Comb Chem 9:86-95. doi:10.1021/ cc060124t
26. Liu G, Li L, Kou B et al (2007) Benzofused tricycles based on 2-quinoxalinol. J Comb Chem 9:70-78. doi:10.1021/cc060034o
27. Zheng L, Xiang J, Dang Q et al (2006) Design and synthesis of a tetracyclic pyrimidine-fused benzodiazepine library. J Comb Chem 8:381-387. doi:10.1021/cc0501615 (Pubitemid 43798303)
28. Kou BB, Zhang F, Yang TM, Liu G (2006) Simultaneous solidphase synthesis of quinoxalinone and benzimidazole scaffold libraries. J Comb Chem 8:841-847. doi:10.1021/cc060074s (Pubitemid 44865675)
29. Zhang J, Zhang L, Zhang S et al (2005) Solution-phase parallel synthesis of a 1,2,7-trialkyl-1H-imidazo[4,5-g]quinoxalin-6-ol library scaffold. JCombChem7:657-664. doi:10.1021/cc050005y (Pubitemid 41764735)
30. Oprea TI (2000) Property distribution of drug-related chemical databases. J Comput Aid Mol Des 14:251-264. doi:10.1023/A:1008130001697 (Pubitemid 30175944)
31. Sadowski J,KubinyiH (1998) Ascoring scheme for discriminating between drugs and nondrugs. J Med Chem 41:3325-3329. doi:10. 1021/jm9706776
32. Hann M, Hudson B, Lewell X et al (1999) Strategic pooling of compounds for high-throughput screening. J Chem Inf Comp Sci 39:897-902. doi:10.1021/ci990423o
33. Frimurer TM, Bywater R, Naerum L et al (2000) Improving the odds in discriminating "drug-like" from "non drug-like" compounds. J Chem Inf Comp Sci 40:1315-1324. doi:10.1021/ci0003810
34. Muegge I, Heald SL, Brittelli D (2001) Simple selection criteria for drug-like chemical matter. JMed Chem 44:1841-1846. doi:10.1021/jm015507e (Pubitemid 32884510)
35. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359
36. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479 (Pubitemid 24167255)
37. De Buck S, Sinha VK, Fenu LAet al (2007) The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos 35:649-659. doi:10.1124/dmd.106.014027 (Pubitemid 46513269)
38. Pang KS, Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653. doi:10.1007/BF01059688 (Pubitemid 8253670)
39. Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39:1-47 (Pubitemid 17048545)
40. Artursson P (1990) Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 79:476-482. doi:10.1002/jps.2600790604 (Pubitemid 20221389)
41. Hou TJ, Zhang W, Xia K et al (2004) ADME evaluation in drug discovery. 5. Correlation of Caco-2 permeation with simplemolecular properties. J Chem Inf Comput Sci 44:1585-1600. doi:10.1021/ci049884m
42. Camenisch G, Alsenz J, Vande Waterbeemd H, Folkers G (1998) Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 6:317-324. doi:10.1016/S0928-0987(97)10019-7 (Pubitemid 28468539)
43. Artursson P, Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880-885. doi:10.1016/0006-291X(91)91647-U
44. Liang E, Chessic K, Yazdanian M (2000) Evaluation of an accelerated Caco-2 cell permeability model. J Pharm Sci 89:336-345.doi:10.1002/(SICI)1520- 6017(200003) (Pubitemid 30152434)
45. Palmgren JJ, Monkkonen J, Jukkola E et al (2004) Characterization of Caco-2 cell monolayer drug transport properties by cassette dosing using UV/fluorescence HPLC. Eur J Pharm Biopharm 57:319-328. doi:10.1016/j.ejpb.2003. 10.016 (Pubitemid 38283710)
46. Rubas W, Jezyk N, Grass GM (1993) Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm Res 10:113-118. doi:10.1023/A: 1018937416447 (Pubitemid 23020847)
47. Hovgaard L, Brondsted H, Buur A, Bundgaard H (1995) Drug delivery studies in Caco-2 monolayers. Synthesis, hydrolysis, and transport of O-cyclopropane carboxylic acid ester prodrugs of various beta-blocking agents. Pharm Res 12:387-392. doi:10.1023/A:1016204602471
48. Yee S (1997) In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res 14:763-766. doi:10.1023/A:1012102522787 (Pubitemid 27281671)
49. Yazdanian M, Glynn SL, Wright JL, Hawi A (1998) Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res 15:1490-1494. doi:10.1023/A:1011930411574 (Pubitemid 28427942)
50. Aungst BJ, Nguyen NH, Bulgarelli JP, Oates-Lenz K (2000) The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm Res 17:1175-1180. doi:10.1023/A:1026402410783
51. Lentz KA, Polli JW, Wring SA et al (2000) Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res 17:1456-1460. doi:10.1023/A:1007692622216 (Pubitemid 32217554)
52. Schipper NG, Osterberg T, Wrange U et al (2001) In vitro intestinal permeability of factor Xa inhibitors: influence of chemical structure on passive transport and susceptibility to efflux. Pharm Res 18:1735-1741. doi:10.1023/A:1013378731183 (Pubitemid 34020430)
53. Usansky HH, Sinko PJ (2005) Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for ka and Fa. J Pharmacol Exp Ther 314:391-399. doi:10.1124/jpet.104.076182 (Pubitemid 41058277)
54. Stenberg P, Norinder U, Luthman K, Artursson P (2001) Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem 44:1927-1937 (Pubitemid 32884517)
55. Zhu C, Jiang L, Chen TM,Hwang KK (2002) Acomparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem 37:399-407. doi:10.1016/S0223-5234(02)01360-0 (Pubitemid 34465549)
56. Ruiz-Garcia A, Lin H, Pla-Delfina JM, HuM (2002) Kinetic characterization of secretory transport of a newciprofloxacin derivative (CNV97100) acrossCaco-2 cellmonolayers. J Pharm Sci 91:2511-2519. doi:10.1002/jps.10244 (Pubitemid 35379409)
57. Rogers D, Hopfinger AJ (1994) Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J Chem Inf Comput Sci 34:854-866. doi:10.1021/ci00020a020
58. Holland JH (1975) Adaptation in natural and artificial systems. University of Michigan Press, Michigan
59. Friedman JH (1991) Multivariate adaptive regression splines. Ann Stat 19:1-67
60. Stockfish TP(2007) Chart-ahead method for decision tree construction7269597, Sep. 11, 2007
61. Sugiyama Y (2005) Druggability: selecting optimized drug candidates. Drug Discov Today 10:1577-1579. doi:10.1016/ S1359-6446(05)03675-5 (Pubitemid 41817598)
62. Hilgers AR, Conradi RA, Burton PS (1990) Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 7:902-910. doi:10.1023/A:1015937605100 (Pubitemid 20349761)
63. Vande Waterbeemd H, Camenisch G (1996) Estimation of Caco- 2 cell permeability using calculated molecular descriptors. Quant Struct-Act Relatsh 15:480-490. doi:10.1002/qsar.19960150604 (Pubitemid 27023202)
64. Palm K, Luthman K, Ungell AL et al (1996) Correlation of drug absorption with molecular surface properties. J Pharm Sci 85: 32-39. doi:10.1021/js950285r (Pubitemid 26029068)
65. Conradi RA, Hilgers AR, Ho NF, Burton PS (1992) The influence of peptide structure on transport across Caco-2 cells. II. Peptide bond modification which results in improved permeability. Pharm Res 9:435-439. doi:10.1023/A: 1015825912542
66. Vande Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction paradise?. Nat Rev Drug Discov 2: 192-204. doi:10.1038/nrd1032 (Pubitemid 37361664)
67. Palm K, Stenberg P, Luthman K, Artursson P (1997) Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 14:568-571. doi:10.1023/A:1012188625088 (Pubitemid 27220272)
68. Kelder J, Grootenhuis PD, Bayada DM et al (1999) Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 16:1514-1519. doi:10.1023/A:1015040217741 (Pubitemid 29510546)
69. Lu JJ, Crimin K, Goodwin JT et al (2004) Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J Med Chem 47:6104-6107. doi:10.1021/jm0306529 (Pubitemid 39507351)
70. Ellens H, Eddy EP, Lee C et al (1997) In vitro permeability screening for identification of orally bioavailable endothelin receptor antagonists. AdvDrugDeliv Rev 23:99-109. doi:10.1016/S0169-409X(96)00428-0 (Pubitemid 27046996)
71. Mandagere AK, Thompson TN,HwangK (2002) Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J Med Chem 45:304-311. doi:10.1021/jm010152k (Pubitemid 34073449)
72. Uetrecht JP, Trager W (2007) Drug metabolism, chemical and enzymatic aspects. Informa Healthcare, New York
73. Lee PH, Cucurull-Sanchez L, Lu J, Du YJ (2007) Development of in silico models for human liver microsomal stability. J Comput Aid Mol Des. doi:10.1007/s10822-007-9124-0
74. Sun L, Zhang SQ, Zhong DF (2004) In vitro identification of metabolites of verapamil in rat liver microsomes. Acta Pharmacol Sin 25:121-128 (Pubitemid 38076089)